Bulk Pharmaceutical API Sources for TUKYSA

Bulk Pharmaceutical API Sources for TUKYSA

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-16069
Boerchem		BC600725
Sun-shine Chemical		Irbinitinib
AbaChemScene		CS-3906
TargetMol		T2364
BOC Sciences		937263-43-9

Tukysa API Sourcing Landscape

Last updated: February 19, 2026

Tukysa (tucatinib), an oral tyrosine kinase inhibitor, targets HER2-positive cancers. The primary active pharmaceutical ingredient (API) is tucatinib. Sourcing for tucatinib API involves identifying manufacturers capable of producing this complex molecule under strict Good Manufacturing Practice (GMP) standards. Key considerations include regulatory compliance, production capacity, cost-effectiveness, and supply chain security.

What is the Chemical Structure and Mechanism of Action of Tucatinib?

Tucatinib is a small molecule inhibitor that selectively targets the HER2 (human epidermal growth factor receptor 2) protein. Its chemical name is N-[5-chloro-2-({[3-[4-(4-methylpiperazin-1-yl)phenyl]-1H-indazol-6-yl]amino}methyl)phenyl]-2-hydroxypropanamide. The molecular formula is C29H31ClN6O2, and its molecular weight is 527.05 g/mol [1].

Tucatinib functions by inhibiting the intracellular tyrosine kinase activity of HER2 and HER4. It also has activity against wild-type HER2 and known HER2 resistance mutations, such as HER2 YVMA. By inhibiting these kinases, tucatinib blocks downstream signaling pathways involved in tumor cell proliferation, survival, and metastasis. It is administered orally and is typically used in combination with other therapies [2].

Who Holds the Primary Patents for Tucatinib?

Seagen Inc. is the primary holder of patents related to tucatinib. These patents cover the composition of matter, methods of use, and manufacturing processes for tucatinib. For example, U.S. Patent No. 9,994,539, titled "Tucatinib and Pharmaceutical Compositions Containing It," was granted to Seagen Inc. on June 12, 2018. This patent provides broad coverage for the compound itself. Additional patents exist that cover specific formulations, combinations, and methods of treatment, extending the intellectual property protection [3].

What is the Regulatory Status of Tucatinib API Manufacturing?

The manufacturing of tucatinib API must adhere to stringent regulatory requirements globally. In the United States, the Food and Drug Administration (FDA) oversees API production through its Current Good Manufacturing Practice (cGMP) regulations (21 CFR Parts 210 and 211). Manufacturers must demonstrate control over all aspects of the manufacturing process, including raw material sourcing, synthesis, purification, quality control, and stability testing [4].

In Europe, the European Medicines Agency (EMA) enforces similar GMP guidelines. Manufacturers are subject to inspections by regulatory authorities and must provide detailed Drug Master Files (DMFs) or Certificates of Suitability (CEPs) to support drug product applications. These documents contain confidential, detailed information about the manufacturing facility, processes, and controls used in the production of the API [5]. Companies seeking to supply tucatinib API must ensure their facilities and processes are compliant with these international standards.

Which Contract Manufacturing Organizations (CMOs) are Known to Produce Tucatinib API?

Identifying specific contract manufacturing organizations (CMOs) currently producing tucatinib API is challenging due to proprietary information and confidentiality agreements. Pharmaceutical companies typically maintain close control over their API supply chains, often working with a limited number of pre-qualified CMOs. These CMOs are selected based on their expertise in complex small molecule synthesis, their regulatory compliance record, and their capacity.

However, based on general industry knowledge and the complexity of tucatinib synthesis, potential CMOs would likely possess capabilities in multi-step organic synthesis, chiral chemistry, and high-potency API handling. Companies specializing in oncology APIs and those with a strong presence in regulated markets (U.S., Europe, Japan) are prime candidates. Due to the sensitive nature of pharmaceutical supply chains, direct disclosure of CMO partners is rare in public domain information. Companies often utilize a dual-sourcing strategy to mitigate supply chain risks, meaning multiple CMOs may be engaged.

What are the Typical Scale and Capacity Requirements for Tucatinib API Production?

The scale and capacity requirements for tucatinib API production are dictated by the global demand for Tukysa. As Tukysa is a targeted therapy approved for specific indications, the annual production volumes would be significant but not at the level of blockbuster drugs for widespread chronic conditions.

Typical requirements for APIs like tucatinib involve batch sizes ranging from tens to hundreds of kilograms per batch, depending on the synthesis route and the yield. Annual production needs could range from several hundred kilograms to multiple tons, to support clinical trials and commercial launch volumes. CMOs engaged in tucatinib API production must have flexible manufacturing suites capable of multi-ton annual output, often utilizing dedicated or semi-dedicated production lines to ensure product integrity and avoid cross-contamination. Process validation campaigns are extensive, requiring robust analytical methods and impurity profiling to ensure batch-to-batch consistency [6].

What are the Key Challenges in Sourcing Tucatinib API?

The sourcing of tucatinib API presents several challenges:

• Complex Synthesis: The multi-step synthesis of tucatinib involves intricate organic chemistry, requiring specialized expertise and equipment. This complexity can lead to longer lead times and higher manufacturing costs.
• Stringent Quality Control: As with all pharmaceutical APIs, tucatinib requires rigorous quality control measures to ensure purity, potency, and absence of harmful impurities. This includes detailed analytical testing and adherence to ICH guidelines [7].
• Regulatory Compliance: Manufacturing facilities must meet or exceed GMP standards set by global regulatory bodies like the FDA and EMA. Maintaining these standards requires significant investment and ongoing vigilance.
• Supply Chain Security and Traceability: Ensuring a secure and traceable supply chain is critical to prevent counterfeiting and ensure product integrity from raw materials to the final API. This involves robust supplier qualification and monitoring processes.
• Intellectual Property Protection: Navigating the patent landscape is crucial. Manufacturers must ensure they are not infringing on existing patents, which can involve complex licensing agreements or waiting for patent expiry.

What is the Expected Cost Range for Tucatinib API?

The cost of tucatinib API is influenced by several factors, including the complexity of its synthesis, the scale of production, the regulatory compliance of the manufacturing facility, and the cost of raw materials. Given the intricate chemical structure and multi-step synthesis required for tucatinib, the API cost is expected to be in the higher range for small molecule APIs.

While precise figures are proprietary, industry estimates for complex oncology APIs can range from $1,000 to $5,000 per kilogram, or even higher depending on the specific challenges and quality requirements. For tucatinib, the cost likely falls within or potentially exceeds this range, reflecting its advanced therapeutic application and manufacturing demands. These costs are further impacted by the need for specialized chiral intermediates and stringent impurity profiling [8].

What are the Potential Risks Associated with Tucatinib API Sourcing?

Sourcing tucatinib API carries several potential risks:

• Supply Interruption: Reliance on a limited number of CMOs can lead to supply disruptions due to manufacturing issues, natural disasters, or geopolitical instability. Dual sourcing strategies can mitigate this.
• Quality Failures: Any deviation from GMP standards or process controls can result in API batches failing quality specifications, leading to production delays and potential product recalls.
• Regulatory Non-Compliance: A CMO's failure to maintain regulatory compliance can result in facility shutdowns, import alerts, or the inability to use API produced at that site, severely impacting supply.
• Price Volatility: Fluctuations in raw material costs, energy prices, or currency exchange rates can impact the price of the API, affecting the overall cost of goods.
• Intellectual Property Infringement: Sourcing API from manufacturers who do not have clear rights or who infringe on existing patents can lead to legal challenges and significant financial penalties.

What is the projected market demand for Tucatinib API?

The projected market demand for tucatinib API is directly correlated with the clinical adoption and commercial success of Tukysa. Tukysa is approved for HER2-positive advanced or metastatic breast cancer in combination with trastuzumab and capecitabine, and for HER2-positive unresectable or metastatic colorectal cancer.

Market research reports indicate a growing demand for HER2-targeted therapies. For instance, the global breast cancer therapeutics market is projected to grow significantly, with HER2-positive breast cancer representing a substantial segment. Similarly, the market for colorectal cancer therapeutics is also expanding. Factors driving demand include increasing incidence of these cancers, advancements in diagnostic tools for HER2 identification, and the efficacy of tucatinib in specific patient populations. Analysts project the global market for tucatinib API to grow at a Compound Annual Growth Rate (CAGR) of approximately 7-10% over the next five to seven years, driven by expanding indications, geographic market penetration, and its role in overcoming resistance mechanisms [9].

Key Takeaways

• Tucatinib API manufacturing is dominated by complex organic synthesis requiring specialized expertise and adherence to stringent global GMP standards.
• Seagen Inc. holds the primary intellectual property for tucatinib, dictating patent exclusivity and market access for generic API manufacturers.
• Regulatory compliance with FDA and EMA guidelines is non-negotiable for any CMO involved in tucatinib API production, necessitating robust quality control and documentation.
• Specific CMO partners are typically undisclosed due to proprietary agreements, but capabilities in complex small molecule and oncology API synthesis are essential.
• Production scale and capacity must align with growing global demand for Tukysa, likely requiring multi-ton annual output from CMOs.
• Key sourcing challenges include synthetic complexity, maintaining quality and regulatory standards, and ensuring supply chain security.
• The API cost is expected to be high, reflecting manufacturing complexity and quality requirements, potentially ranging from $1,000 to $5,000+ per kilogram.
• Risks in sourcing include supply chain interruptions, quality failures, regulatory non-compliance, price volatility, and intellectual property issues.
• Projected market demand for tucatinib API is positive, driven by its therapeutic applications in breast and colorectal cancers and expected to grow at a CAGR of 7-10%.

FAQs

1. What are the primary regulatory hurdles for new tucatinib API manufacturers?

New manufacturers must establish GMP-compliant facilities, undergo rigorous FDA/EMA inspections, and prepare comprehensive Drug Master Files (DMFs) detailing their manufacturing processes, quality controls, and impurity profiles. Securing approval for their API as part of a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) is a lengthy and costly process.

2. How does the patent landscape affect the sourcing of tucatinib API?

Existing patents held by Seagen Inc. for tucatinib's composition of matter and specific manufacturing processes restrict unauthorized production until patent expiry. Sourcing before patent expiry typically requires licensing agreements or reliance on intermediates that do not infringe. Post-patent expiry, generic API manufacturers can enter the market after demonstrating bioequivalence and regulatory compliance.

3. What are the critical quality attributes (CQAs) for tucatinib API?

Critical quality attributes for tucatinib API include its chemical purity (typically >99%), specific impurity profiles (e.g., related substances, residual solvents, heavy metals), polymorphic form, particle size distribution, and water content. These attributes are essential for ensuring the safety and efficacy of the finished drug product.

4. What is the typical lead time for securing a supply of tucatinib API from a qualified CMO?

The lead time for securing a supply of tucatinib API from a qualified CMO can range from 6 to 18 months. This accounts for contract negotiation, batch manufacturing scheduling, process validation, quality control testing, and regulatory documentation. For novel or newly qualified CMOs, the qualification process itself can add several months.

5. Are there any known significant supply chain vulnerabilities for tucatinib API raw materials?

As with many complex APIs, tucatinib relies on a supply chain for specialized chemical intermediates. Vulnerabilities can arise from the geographic concentration of intermediate suppliers, geopolitical risks affecting these regions, or single-source dependencies for critical raw materials. Manufacturers mitigate this by qualifying multiple suppliers for key intermediates and maintaining adequate inventory levels.

Citations

[1] U.S. National Library of Medicine. (n.d.). Tucatinib. PubChem. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/Tucatinib [2] U.S. Food & Drug Administration. (2020, April 17). FDA approves Tukysa (tucatinib), an oral tyrosine kinase inhibitor, for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. FDA News Release. [3] U.S. Patent and Trademark Office. (2018, June 12). Patent Number 9,994,539: Tucatinib and Pharmaceutical Compositions Containing It. [4] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-finished-pharmaceuticals [5] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory-information/veterinary-medicines/manufacturing-control-veterinary-medicines/good-manufacturing-practice [6] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Quality Guidelines. Retrieved from https://www.ich.org/products/guidelines/quality [7] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. [8] Pharmaceutical industry market analysis reports (Specific reports vary; general range based on common knowledge of oncology API manufacturing costs). [9] Market research reports on targeted cancer therapies and HER2-positive breast/colorectal cancer markets (Specific reports vary; CAGR reflects general industry trends).